CLINICAL
TRIALS
OF
BIVALENT
ANEW
JERSEY76AVICTORIA75
INFLUENZA
VACCINES
IN
HIGHRISK
CHILDREN
VARIOUS
DOSES
OF
TWO
WHOLEVIRUS
AND
ONE
SPLITPRODUCT
BIVALENT
INFLUENZA
ANEW
JERSEY76AVICTORIA75
VACCINES
WERE
ADMINISTERED
TO
253
CHILDREN
AGED
SIX
TO
18
YEARS
THERE
WERE
NO
STATISTICALLY
SIGNIFICANT
DIFFERENCES
IN
EITHER
REACTIVITY
OR
HUMORAL
ANTIBODY
RESPONSE
AMONG
THE
167
CHILDREN
IN
SEVEN
CHRONIC
DISEASE
CATEGORIES
AND
86
HEALTHY
CHILDREN
THE
WHOLEVIRUS
VACCINES
WERE
ASSOCIATED
WITH
UNACCEPTABLY
HIGH
RATES
OF
REACTION
WHEN
GIVEN
IN
SUFFICIENTLY
ANTIGENIC
INITIAL
DOSES
BUT
WERE
RELATIVELY
NONREACTIVE
WHEN
USED
FOR
BOOSTER
IMMUNIZATION
SPLITPRODUCT
VACCINES
WERE
NO
MORE
REACTIVE
THAN
PLACEBO
ALL
VACCINE
PREPARATIONS
INDUCED
ADEQUATE
SEROCONVERSION
RATES
AND
PROTECTIVE
TITERS
OF
ANTIBODY
TO
AVICTORIA
VIRUS
AFTER
ONE
DOSE
AND
TO
ANEW
JERSEY
VIRUS
AFTER
TWO
DOSES
